Eli Lilly and Company (LLY)vsNovo Nordisk A/S (NVO)
LLY
Eli Lilly and Company
$1,347.11
-0.30%
HEALTHCARE · Cap: $1.27T
NVO
Novo Nordisk A/S
$37.82
-2.70%
HEALTHCARE · Cap: $177.74B
Smart Verdict
WallStSmart Research — data-driven comparison
Novo Nordisk A/S generates 286% more annual revenue ($333.65B vs $86.46B). NVO leads profitability with a 33.9% profit margin vs 31.9%. LLY appears more attractively valued with a PEG of 1.33. LLY earns a higher WallStSmart Score of 74/100 (B).
LLY
Strong Buy74
out of 100
Grade: B
NVO
Buy59
out of 100
Grade: C
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 68 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 51.2%
Revenue surging 38.6% year-over-year
Generating 8.2B in free cash flow
Attractively priced relative to earnings
Every $100 of equity generates 52 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 40.1%
Generating 28.1B in free cash flow
Large-cap with strong market position
Areas to Watch
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 29.8x book value
Weak financial health signals
Expensive relative to growth rate
Earnings declined 15.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.9% and operating margin at 51.2%. Revenue growth of 38.6% demonstrates continued momentum.
Bull Case : NVO
The strongest argument for NVO centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 33.9% and operating margin at 40.1%.
Bear Case : LLY
The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 46.3x leaves little room for execution misses.
Bear Case : NVO
The primary concerns for NVO are Piotroski F-Score, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
LLY profiles as a growth stock while NVO is a mature play — different risk/reward profiles.
LLY carries more volatility with a beta of 0.39 — expect wider price swings.
LLY is growing revenue faster at 38.6% — sustainability is the question.
NVO generates stronger free cash flow (28.1B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (74/100 vs 59/100), backed by strong 31.9% margins and 38.6% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Novo Nordisk A/S
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?